Deutsche Version

TRU-ID is situated at the heart of the University Hospital Cologne campus. In our modern laboratories covering biosafety levels (BSL) 1 to 3 at the Center for Molecular Medicine Cologne (CMMC), we do exciting research on viral, bacterial and fungal pathogens. An additional focus of our consortium is research on SARS-CoV-2, especially on the role of the innate immune system, the Post-COVID syndrome, and clinical data on the duration of SARS-CoV2 immunity. Our activities are directed at translational research with the ultimate goal of improving patient wellbeing. The central localization of our unit allows for timely processing of patient material in several bedside-to-bench studies.

A key unit is the modern BSL3 facility, which is maintained under negative air pressure for pathogen containment. The facility is dedicated to the identification of novel bioactive substances targeting multidrug resistant Tuberculosis and other highly contagious pathogens. With our research, we also try to answer fundamental scientific questions on host-pathogen interaction, again with the goal of future clinical application as host-directed therapies, new vaccines and diagnostics. To this end, five research groups with different scientific backgrounds have joined forces to form TRU-ID, with the aim of creating synergies. In addition, there are various collaborations with laboratories within and outside the University Hospital of Cologne, for example with the group of Dr. Philipp Schommers. The TRU-ID unit is headed by Priv.-Doz. Dr. Dr. Jan Rybniker.

Translational Research Unit – Infectious Diseases (TRU-ID)

Priv.-Doz. Dr. Jan Rybniker
Center for Molecular Medicine Cologne (CMMC)
Robert Koch Str. 21
50931 Cologne

Phone +49 221 478-89608 (laboratory)
Phone  +49 221 478-89611 (office)
Email jan.rybniker@uk-koeln.de